on Cambrex
Cambrex Announcing Progress in US and European Expansion Efforts
Cambrex, a global leader in contract development and manufacturing, has completed initial engineering studies for its new large-scale active pharmaceutical ingredient (API) manufacturing plant in Charles City, Iowa. This marks a significant step in its $120 million investment plan to enhance U.S. API production. Construction is expected to start in late 2026.
The expansion in Charles City will include a new plant with 140,000 liters of capacity, featuring advanced reactors and equipment. This new facility will boost the site's large-scale manufacturing capacity by 20%, catering to complex chemistries and positioning Cambrex as a key partner in pharmaceutical innovation.
In Europe, Cambrex is also progressing with a $30 million expansion at its Milan, Italy site, set to enhance analytical development and process R&D. This project, anticipated to conclude in late 2027, highlights Cambrex's commitment to meeting rising demands for advanced CDMO services.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Cambrex news